Glycoproteomics-based Liquid-biopsy LDT Development Service for Prostate Cancer

Glycoproteins of Prostate Cancer

Prostate cancer (PCa) ranks as the second most commonly diagnosed cancer among men. While the serum prostate-specific antigen (PSA) test is utilized for early PCa detection, its accuracy is limited, leading to debates due to the risks of excessive diagnosis and treatment.

Emerging evidence establishes aberrant glycosylation as a dependable hallmark of cancer. The majority of the tumor markers, including PSA, are glycoproteins. Various glycan modifications of PSA, such as sialylation, mainly α2,3-sialylation, core fucosylation, branched N-glycans, and LacdiNAc groups, have been consistently linked to the potential to differentiate between benign prostate conditions and cancer. Additionally, these glycan alterations offer promise in distinguishing various stages of PCa development and aggressiveness. An extensive investigation into glycoproteomics, particularly in the case of PSA, through non-invasive methods becomes essential for a thorough assessment and diagnosis of prostate diseases.

Glycoproteomics-based Liquid-biopsy LDT Development for PCa at Creative Biolabs

Creative Biolabs has pioneered an advanced Glycoproteomics-based Liquid-biopsy LDT Platform, aimed at comprehending the implications of glycosylation alterations in prostate diseases.

• Analysis of PSA glycosylation

This platform enables comprehensive glycan profiling for individual proteins, such as PSA. Our LDT method selectively enriches PSA from biological samples by immunoaffinity capture. Following enrichment, PSA is reduced and alkylated before digestion with trypsin. Subsequently, the separation of glycopeptides is performed by capillary electrophoresis (CE), which is coupled with MALDI-MS detection, followed by rigorous data processing. This method allows us to uncover changes in the glycan patterns of PSA when compared to healthy controls.

• Analysis of global glycoproteins

In addition to glycan profiling of a single protein, we offer comprehensive glycoproteomic analysis for global glycoproteins present in samples based on mass spectrometry. Our LDT services include but are not limited to glycopeptide mapping, site occupancy analysis, glycan profiling, intact glycopeptides analysis, and characterization of general glycoproteins.

Fig.1 Workflow of global glycoproteins analysis.

Advantages

Fig.1 Workflow of global glycoproteins analysis.

Published Data

Technology: Glycoproteomic analysis

Journal: Clinical Genitourinary Cancer

Published: 2020

Results: LacdiNAc-glycosylated prostate-specific antigen is a potential marker for detecting PCa and selecting candidates for radical prostatectomy (RP).

Fig.2 Serum levels and ROC analyses of PSA and LDN-PSA.¹

Creative Biolabs provides state-of-the-art liquid biopsy LDT services based on glycoproteomics, offering significant potential for elucidating the impact of glycosylation alterations in prostate diseases. Please feel free to contact us or submit an inquiry directly for more information.

Reference

1. Inoue, Takahiro, et al. "LacdiNAc-glycosylated prostate-specific antigen density is a potential biomarker of prostate cancer." Clinical Genitourinary Cancer 18.1 (2020): e28-e36.

Related Services:

1. NASH
2. NSCLC
3. Pancreas Carcinoma
4. Renal Cell Carcinoma
5. Nasopharyngeal Carcinoma
6. HCC
7. Advanced Adenoma
8. Colorectal Cancer